Go to the list of all blogs
M. Benett's Avatar
published in Blogs
Jun 09, 2026
AXTI Stock: -21% Drop in 30 Days After +130% Quarterly Advance

AXTI Stock: -21% Drop in 30 Days After +130% Quarterly Advance

Key Takeaways

  • AXTI stock declined approximately 21% over the past 30 days amid a broader pullback in AI-related semiconductor shares.
  • Over the last quarter, the stock rose more than 130%, driven by strong demand for indium phosphide substrates tied to AI infrastructure.
  • Q1 2026 results showed revenue growth and an adjusted EPS beat, supported by a major capital raise for capacity expansion.
  • Recent sector-wide AI selloffs and profit-taking contributed to the short-term price decline.
  • Analyst price targets were raised significantly during the quarter, reflecting improved growth outlook.

AXT, Inc. (AXTI) and Its Position in the Market

AXT, Inc. develops and manufactures high-performance compound and single-element semiconductor wafer substrates, including indium phosphide (InP), gallium arsenide (GaAs), and germanium (Ge). The company supplies materials critical for applications in optical communications, 5G wireless infrastructure, and data center technologies. Its focus on indium phosphide positions it to benefit from surging demand in artificial intelligence (AI) data centers and high-speed networking. Strong exposure to these high-growth areas helps explain the stock’s sharp quarterly advance followed by a more recent correction as sentiment shifted. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

AXTI Stock Price Performance: Last 30 Days vs. Quarter

Over the last 30 days, AXTI shares fell approximately 21%, moving from levels near $115 to a closing price of $90.78 on June 8, 2026. The decline occurred in a relatively volatile manner with several sharp daily drops, including one session exceeding 15%.

Over the past quarter, the stock advanced more than 130%, rising from the low $30s in early March 2026 to the $90 range by early June. The quarterly move featured a strong upward trend fueled by positive company developments, though the final weeks showed increased volatility and a reversal from peak levels above $140.

What Drove the Recent -21% Move in AXTI Shares

The primary driver of the 30-day decline was a broad selloff across AI and semiconductor stocks. AXTI participated in this sector rotation as investors took profits following the earlier rally. Specific sessions saw outsized moves, including a nearly 16% drop on one day tied to the wider AI-sector correction. No major company-specific negative news emerged; instead, the pullback reflected macroeconomic sentiment shifts and reduced risk appetite in high-growth technology names. Trading volume remained elevated during the decline, consistent with profit-taking rather than fundamental deterioration.

What Powered the +130% Quarterly Rally in AXTI

The quarterly surge was powered by robust demand for indium phosphide substrates used in AI data center optical components. First-quarter 2026 results delivered revenue of $26.9 million, up from $19.4 million a year earlier, along with an adjusted earnings beat. Management provided upbeat Q2 guidance and highlighted a backlog exceeding $100 million. A $632.5 million capital raise, plus an over-allotment, funded indium phosphide capacity expansion. Analyst firms including Wedbush and B. Riley raised price targets substantially. These factors created sustained positive momentum through much of the period before sector-wide pressures emerged.

Trending AI Robots

In my own research process, I often review Tickeron’s Trending AI Robots page to explore automated trading approaches. It showcases a curated selection of the platform’s top-performing AI trading bots. Tickeron offers hundreds of AI trading bots that trade thousands of tickers, yet only the highest-performing and most relevant bots appear in this section. Bots differ in strategy, timeframe, and performance metrics, allowing users to explore automated approaches suited to various market conditions. The page provides transparent metrics for each bot to support informed evaluation. Explore the full selection on the Trending AI Robots page.

AXTI Stock Forecast Drivers: What Investors Should Watch Next

Investors should monitor upcoming quarterly results for continued revenue growth and execution on indium phosphide expansion plans. Key factors include the timing of export permits, progress on new capacity coming online, and any updates to the order backlog. Broader semiconductor industry trends, AI infrastructure spending, and macroeconomic conditions such as interest rates will influence sentiment. Potential risks include supply-chain constraints or shifts in customer demand patterns. Strategic developments, including any further capital allocation decisions, also merit attention. One thing that stands out is how execution on the capacity buildout could shape the next leg of growth.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: AXTI

AXTI in upward trend: price rose above 50-day moving average on September 16, 2026

AXTI moved above its 50-day moving average on September 16, 2026 date and that indicates a change from a downward trend to an upward trend. In 43 of 47 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on September 16, 2026. You may want to consider a long position or call options on AXTI as a result. In 62 of 80 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 77%.

The Moving Average Convergence Divergence (MACD) for AXTI just turned positive on September 17, 2026. Looking at past instances where AXTI's MACD turned positive, the stock continued to rise in 37 of 44 cases over the following month. The odds of a continued upward trend are 84%.

The 10-day moving average for AXTI crossed bullishly above the 50-day moving average on September 17, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 13 of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 81%.

Following a +5.93% 3-day Advance, the price is estimated to grow further. Considering data from situations where AXTI advanced for three days, in 221 of 279 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.

The Aroon Indicator entered an Uptrend today. In 214 of 248 cases where AXTI Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 86%.

Bearish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 10 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where AXTI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.

AXTI broke above its upper Bollinger Band on September 21, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 22 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. AXTI’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Profit vs. Risk Rating rating for this company is 57 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 60, placing this stock slightly better than average.

The Tickeron SMR rating for this company is 90 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of 98 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.467) is normal, around the industry mean (8.078). AXTI's P/E Ratio (2455.833) is considerably higher than the industry average of (161.623). AXTI's Projected Growth (PEG Ratio) (0.100) is slightly lower than the industry average of (0.801). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (26.596) is also within normal values, averaging (27.897).

Notable companies

The most notable companies in this group are Lam Research Corp (NASDAQ:LRCX), Applied Materials (NASDAQ:AMAT), KLA Corporation (NASDAQ:KLAC), Teradyne (NASDAQ:TER), Ambarella (NASDAQ:AMBA).

Industry description

The electronic production equipment industry makes equipment used to produce semiconductors. Such equipment includes wafer fabrication, plasma etching and photo-resist processing equipment. The industry also makes chemical vapor deposition processing systems and photomasks, which are high-purity quartz plates that contain patterns to define integrated circuits layouts. Applied Materials, Inc., Lam Research Corporation, and KLA-Tencor Corporation are examples of electronic production equipment manufacturing companies.

Market Cap

The average market capitalization across the Electronic Production Equipment Industry is 63.66B. The market cap for tickers in the group ranges from 326.86K to 671.68B. ASML holds the highest valuation in this group at 671.68B. The lowest valued company is AVSR at 326.86K.

High and low price notable news

The average weekly price growth across all stocks in the Electronic Production Equipment Industry was 3%. For the same Industry, the average monthly price growth was 11%, and the average quarterly price growth was 12%. INTT experienced the highest price growth at 28%, while SMTK experienced the biggest fall at -30%.

Volume

The average weekly volume growth across all stocks in the Electronic Production Equipment Industry was 15%. For the same stocks of the Industry, the average monthly volume growth was -12% and the average quarterly volume growth was -63%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 63
P/E Growth Rating: 34
Price Growth Rating: 42
SMR Rating: 71
Profit Risk Rating: 59
Seasonality Score: 27 (-100 ... +100)
View a ticker or compare two or three
AXTI
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a manufactures of high-performance compound semiconductor substrates

Industry ElectronicProductionEquipment

Industry
Electronic Production Equipment
Address
4281 Technology Drive
Phone
+1 510 438-4700
Employees
1072
Web
http://www.axt.com
Interact to see
Advertisement
UBXG stock surged +79% over the last 30 days, driven by heightened trading volume and positive market sentiment amid broader technology sector trends. Over the past quarter, the stock rose +61%, reflecting recovery from earlier lows near its 52-week bottom.
CVGI stock surged approximately +89% over the last 30 days, driven by strong Q4 2025 earnings beat on revenue and positive 2026 guidance. Over the past quarter, shares rose about +126%, reflecting improved profitability, debt reduction, and a key partnership announcement.
SAFX stock surged +104% over the past 30 days, driven by positive updates on a $10 million capital raise and merger progress. Over the past quarter, the stock rose +44%, reflecting recovery from lows amid renewable energy sector interest and strategic developments.
LONA stock surged +80% over the past 30 days, driven by positive analyst upgrades, executive appointments, and full-year financial updates highlighting pipeline progress. Over the past quarter, shares rose +48%, reflecting improved investor sentiment in biotech amid clinical advancements.
Lifetime Brands (LCUT) stock surged +77% over the last 30 days, driven by a strong Q4 earnings beat and a Zacks Rank #1 (Strong Buy) upgrade that reflects an improved earnings outlook. Over the past quarter, shares rose +48%, supported by profitability gains despite softer sales, with adjusted EBITDA reaching $50.8 million for full-year 2025.
CURV stock surged approximately +73% over the last 30 days, driven primarily by a positive reaction to Q4 and fiscal 2025 earnings that beat expectations on EPS and revenue. Over the past quarter, the stock is up around +55%, reflecting recovery from lows near $1 amid ongoing store optimization and sub-brand launches
Blaize Holdings, Inc. (BZAI) focuses on artificial intelligence (AI)-enabled edge computing solutions, offering programmable AI processors and platforms for verticals such as smart cities, defense, retail, and enterprise markets. The company's core revolves around hardware like the Graph Streaming Processor (GSP) AI accelerator, compute cards, and software tools including Blaize AI Studio—a no-code/low-code environment for deploying AI models without source code expertise. Based in El Dorado Hills, California, and founded in 2010, it went public through a merger in early 2025.
Comstock Holding Companies, Inc. (CHCI) operates as an asset manager, developer, and operator of mixed-use and transit-oriented properties, mainly in the greater Washington, D.C. metropolitan area. The company targets high-growth urban and suburban markets, overseeing a portfolio that spans residential, commercial, hospitality, and parking assets near key metro stations. Its asset-light, fee-based model delivers recurring revenue through property management, leasing, development services, and asset recapitalization for institutional investors, family offices, and governments.
ARM stock surged +26% over the past 30 days, driven by announcements of in-house chip production and strong analyst upgrades amid AI enthusiasm. Over the past quarter, the stock climbed +38%, reflecting robust Q3 earnings beat with 26% revenue growth and data center royalty doubling.
Sable Offshore Corp. (SOC) is an independent oil and gas company focused on offshore operations in federal waters off California. The company owns and operates three platforms in the Santa Ynez Unit (SYU), spanning 16 federal leases across approximately 76,000 acres, along with subsea pipelines for crude oil, natural gas, and produced water transport to onshore facilities. Its core business model centers on restarting and developing prolific fields like the SYU, which had been idle due to regulatory and legal hurdles following a 2015 pipeline spill.
From what I see, Cheniere Energy Partners (CQP) holds a commanding position through its ownership and operation of the Sabine Pass LNG terminal in Louisiana, the largest LNG production facility in the U.S. with approximately 30 million tonnes per annum (mtpa) capacity across six trains, alongside the connected Creole Trail Pipeline. This setup makes CQP a leader in U.S. LNG exports, which have accounted for about 11% of global supply in recent years. The company's ~80% contracted production through long-term sale and purchase agreements (SPAs) provides revenue stability, with weighted average remaining lives of around 13 years.
In my view, Regeneron Pharmaceuticals holds a strong leadership position in biotechnology, thanks to its proprietary VelociSuite technologies, including VelocImmune for fully human antibody discovery. This enables a robust pipeline across immunology, oncology, ophthalmology, and rare diseases. The company's integrated model—from discovery to commercialization—drives high R&D productivity, with approximately 45 clinical programs and key partnerships like Sanofi for Dupixent and Bayer for EYLEA.
As I review argenx SE's place in the market, its strong footing in immunology stands out. This commercial-stage biopharmaceutical company focuses on differentiated antibody therapies for severe autoimmune diseases. The flagship product, VYVGART (efgartigimod), a first-in-class neonatal Fc receptor (FcRn) inhibitor, has secured leadership in generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP), with approvals across the U.S., Europe, and Japan. The Immunology Innovation Program (IIP) fuels a robust pipeline, featuring next-generation FcRn candidates like ARGX-213 and ARGX-124, alongside first-in-class assets such as empasiprubart (C2 inhibitor, ARGX-117) and adimanebart (MuSK agonist).
I've long admired Alnylam Pharmaceuticals as the pioneer in RNA interference (RNAi) therapeutics, a gene-silencing technology that has delivered six approved products, including AMVUTTRA (vutrisiran), ONPATTRO (patisiran), GIVLAARI (givosiran), and OXLUMO (lumasiran). The company's proprietary platform, enhanced by GalNAc conjugation for liver targeting and emerging extra-hepatic delivery innovations, creates a solid competitive moat in precision genetic medicines.
As I review BeOne Medicines AG's position in the oncology space, what stands out is its role as a global leader with a diversified portfolio that includes both commercial-stage therapies and a deep pipeline targeting hematologic and solid tumors. The flagship product, BRUKINSA (zanubrutinib), a Bruton's Tyrosine Kinase (BTK) inhibitor, has secured approvals in over 75 markets, solidifying its dominance in chronic lymphocytic leukemia (CLL) and other blood cancers. This is complemented by TEVIMBRA (tislelizumab), an anti-PD-1 antibody approved in more than 50 markets for various indications, which broadens its reach in immunotherapy.
Rio Tinto holds a premier position as one of the world's largest mining companies, anchored by low-cost, Tier 1 assets. Its Pilbara iron ore operations in Australia deliver industry-leading margins, thanks to integrated rail and port infrastructure that gives it a structural cost advantage over higher-cost producers. In copper, the company has significant stakes in Escondida, the world's largest copper mine, and full ownership of Oyu Tolgoi in Mongolia, setting it up well to benefit from tightening supply as demand surges for electrification and renewables.
I've always been impressed by how Visa (V) commands the global payments landscape. As an open-loop network, it connects issuers, acquirers, merchants, and consumers without issuing cards or extending credit itself. The VisaNet platform processes over 65,000 transactions per second across more than 200 countries, supporting a ~52% share of the global credit card market and ~60% of debit. This scale generates powerful network effects, where greater adoption benefits everyone involved and creates formidable barriers to entry.
Following the Kenvue consumer health spin-off, Johnson & Johnson has transformed into a focused healthcare leader, emphasizing Innovative Medicine (pharmaceuticals) and MedTech (devices). In my view, this repositioning sharpens the company's edge in high-margin areas such as oncology, immunology, neuroscience, cardiovascular, surgery, and vision, where its diversified portfolio and R&D efficiency provide clear competitive advantages.
I've long appreciated ASML Holding N.V.'s dominant position in the semiconductor lithography market. The company commands over 90% share in advanced deep ultraviolet (DUV) immersion systems and 100% in EUV lithography—the critical technology for chips below 7nm nodes used in AI, high-performance computing, and memory. This near-monopoly comes from decades of R&D investment, exclusive partnerships like Zeiss for optics, and a vast installed base that generates steady service revenue. From what I see, competitors such as Nikon and Canon remain far behind in EUV, sticking to mature nodes.
I've been watching Micron Technology (MU) closely through its recent volatility, which mirrors the semiconductor sector's heightened sensitivity to AI demand and supply constraints. The stock saw a sharp post-earnings sell-off tied to elevated capital expenditure plans, yet it has rebounded with surging DRAM prices—up 90-95%—and memory suppliers booked out for years. From what I see, broader tech optimism, including key partnerships and persistent supply tightness, is driving upward momentum. This positions MU as a pivotal player in high-bandwidth memory (HBM) for data centers. Trading near recent highs around $368, the shares highlight investor focus on Micron's critical role in the AI infrastructure expansion under these constrained industry conditions.